Get started
Award

81972164

Funded outputs count: 26
Funder award ID: 81972164
OpenAlex ID: G7320175693
Crizotinib or vebreltinib response and resistance in advanced non-small cell lung cancer with MET exon 14 skipping
2026 · Jiao Yang, Jiao Yang, et al. · Discover Oncology
Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non‐Small Cell Lung Cancer With ROS 1 Rearrangement
2026 · Quan‐Quan Tan, Yu‐Qing Chen, et al. · Cancer Medicine
PDF
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS)
2026 · Anna Li, Wei-Neng Feng, et al. · Nature Communications · 7
PDF
Comparing the effect of traditional and novel tyrosine kinase inhibitors for epidermal growth factor receptor exon 20 insertions by molecular dynamics simulation
2025 · Ke-Jun Liu, Tao Jiang, et al. · Journal of International Medical Research
Transcriptomic analysis of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals distinct subgroups and precision therapy opportunities
2025 · Hao Sun, Chan-Yuan Zhang, et al. · Biomarker Research · 8
PDF
The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of EGFR exon 20: A retrospective analysis
2025 · Ke-Jun Liu, Hong-Rui Li, et al. · Science Progress
PDF
Advances in immuno-based and targeted therapies in extensive-stage small cell lung cancer
2025 · Xiao-Tong Zou, Jie Huang, et al. · Therapeutic Advances in Medical Oncology · 6
Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer patients
2024 · Cheng-Di Weng, Ke-Jun Liu, et al. · Translational Lung Cancer Research · 11
Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen
2024 · Ke-Jun Liu, Hong-Rui Li, et al. · Lung Cancer · 10
PDF
Mixed response to the first‐line treatment of KRAS G12C inhibitor, sotorasib, in non‐small cell lung cancer: A brief report
2024 · Jiao Yang, Jiao Yang, et al. · Clinical Case Reports · 2
PDF
Plasma ddPCR for the detection of MET amplification in advanced NSCLC patients: a comparative real-world study
2024 · Jun-Wei Su, Cheng-Di Weng, et al. · Therapeutic Advances in Medical Oncology · 4
Molecular features and clinical outcomes of EGFR-mutated, MET-amplified non-small-cell lung cancer after resistance to dual-targeted therapy
2024 · Mei-Mei Fang, Jiang-Tao Cheng, et al. · Therapeutic Advances in Medical Oncology · 3
Rationale and Design of a Phase II Trial of Combined Serplulimab and Chemotherapy in Patients with Histologically Transformed Small Cell Lung Cancer: a Prospective, Single-arm and Multicentre Study
2023 · J. Huang, X.-H. Zhang, et al. · Clinical Oncology · 4
PDF
Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
2023 · Shi-Ling Zhang, Chan-Yuan Zhang, et al. · Journal of Thoracic Disease · 12
PDF
Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study
2023 · Han-Min Wang, Chan-Yuan Zhang, et al. · Cell Reports Medicine · 192
The predictive value of YAP-1 and POU2F3 for the efficacy of immuno-chemotherapy in extensive-stage SCLC patients
2023 · Yu-Qing Chen, Ling-Ling Gao, et al. · Cancer Treatment and Research Communications · 4
Pathological characteristics and tumour immune microenvironment of lung malignancies with RET rearrangement
2023 · Qing-Yun Gao, Fa-Man Xiao, et al. · Cancer Treatment and Research Communications · 1
Molecular pathological characteristics and tumour immune microenvironment of lung malignancies with RET rearrangement
2022 · Qing-Yun Gao, Fa-Man Xiao, et al. · Research Square
PDF
Response to ABCP Regimen in a ROS1Rearranged Lung Adenocarcinoma Patient with Brain Metastases and High PD-L1 Expression: A Case Report
2022 · Quan-Quan Tan, Yu-Qing Chen, Ming-Ying Zheng, Yu-Fa Li, · Journal of Oncology Research and Therapy
PDF
Clinical outcomes of EGFR +/ METamp + vs. EGFR +/ METamp ‐ untreated patients with advanced non‐small cell lung cancer
2022 · Kai‐Cheng Peng, Jun‐Wei Su, et al. · Thoracic Cancer · 16
Response to Icotinib Plus Chemotherapy in Pulmonary Atypical Carcinoid Harboring the EGFR L858R Mutation: A Brief Report
2021 · Yu-Qing Chen, Yu-Fa Li, et al. · JTO Clinical and Research Reports · 5
PDF
Clinicopathological features and resistance mechanisms in HIP1‐ALK ‐rearranged lung cancer: A multicenter study
2021 · Jin Kang, Qiu‐Mei Deng, et al. · Genes Chromosomes and Cancer · 13
Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer
2020 · Jin Kang, Xu-Chao Zhang, et al. · Frontiers in Oncology · 37
PDF
Predictive and Prognostic Potential of TP53 in Patients With Advanced Non–Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901)
2020 · Xiang-Meng Li, Wen-Feng Li, et al. · Clinical Lung Cancer · 60
Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study
2020 · Jiang-Tao Cheng, Yi-Hui Yao, et al. · Lung Cancer · 7
Year
Topic